Safety and efficacy of TACE combined with immune checkpoint inhibitors plus molecular targeted therapies in older adults with unresectable hepatocellular carcinoma.

J Cancer Res Clin Oncol · 2025 · PMC12226637 · PMID 40610799

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Recently, the EMERALD-1 phase III trial demonstrated that TACE in combination with durvalumab and bevacizumab had a highly significant improvement in progression-free survival (PFS) versus TACE alone for unresectable HCC [ 14 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.